Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Nov 2023 - The FDA's approval of Eli Lillys Zepbound (tirzepatide) represents a significant advancement in obesity treatment, as it uniquely targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
For a broader look at safety across the peptide landscape, the benefits and risks of peptides guide provides valuable context
Common side effects include: Nausea Constipation Diarrhea Vomiting Stomach discomfort Indigestion Reduced appetite Bloating Some clinical studies reported higher rates of nausea at certain doses, but side effects when compared between medications vary by study and patient group
These foods promote inflammation, provide poor satiety per calorie, and often worsen gastrointestinal symptoms
Should You Push Through GLP-1 Fatigue or Rest
